Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Assessment Of Early Cytogenetic Response By 3 Months Versus >3-6 Months Or No Response By 6 Months As a Predictor Of Long-Term Clinical Outcomes In a Phase 1/2 Study Of Bosutinib In Chronic Phase CML

Jorge E. Cortes, MD, H. Jean Khoury, MD, Andreas Hochhaus, MD, Jane F Apperley, MD, Stephen G. O'Brien, MD, Eric Leip, PhD, Kathleen Turnbull, MD, Maureen G. Conlan, MD, Hagop M. Kantarjian, MD, Tim H. Brümmendorf, MD

Blood (2013) 122 (21): 1484.

https://doi.org/10.1182/blood.V122.21.1484.1484

Published: 2013

Journal Articles

International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Michael Deininger, MD, PhD, Stephen G O'Brien, MD, PhD, François Guilhot, MD, John M Goldman, DM, FCRP, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, Jerald P. Radich, MD, Alan K. Hatfield, MD, FACP, Manisha Mone, PhD, Jeiry Filian, John Reynolds, Insa Gathmann, Richard A. Larson, MD, Brian J. Druker, MD

Blood (2009) 114 (22): 1126.

https://doi.org/10.1182/blood.V114.22.1126.1126

Published: 2009

Journal Articles

Steady-State Imatinib Trough Levels as Well as Dose Interruptions Are Associated with Clinical Response (CCyR and MMR) and Adverse Events (AEs) in Patients with Chronic Myeloid Leukemia (CML) Receiving IM as Frontline Therapy.

Richard A. Larson, MD, Yen Lin Chia, PhD, Camille Granvil, PhD, François Guilhot, MD, Brian J. Druker, MD, Stephen G O'Brien, MD, PhD, Michele Baccarani, MD, Timothy P. Hughes, MD, MBBS, Jerry R. Nedelman, PhD, Yanfeng Wang, PhD

Blood (2009) 114 (22): 2213.

https://doi.org/10.1182/blood.V114.22.2213.2213

Published: 2009

Journal Articles

A Gene Expression Signature of CD34+ Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance.

Shannon McWeeney, Gregory Yochum, Lucy C. Pemberton, MD, FRCPath, Marc Loriaux, MD, PhD, Kristina Vartanian, Stephanie G Willis, Beth Wilmot, Yaron Turpaz, Raji Pillai, Mary Mac partlin, Jennifer Snead, PhD, Brian J. Druker, MD, Stephen G O'Brien, MD, PhD, Junia V. Melo, MD, PhD, Thoralf Lange, MD, Christina Harrington, Michael Deininger, MD, PhD

Blood (2009) 114 (22): 508.

https://doi.org/10.1182/blood.V114.22.508.508

Published: 2009

Journal Articles

Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP)

Timothy P Hughes, MD, Andreas Hochhaus, MD, Susan Branford, PhD, Martin C Müller, MD, Letizia Foroni, MD, PhD, FRCPath, Brian J. Druker, MD, François Guilhot, MD, Richard A. Larson, MD, Stephen G O’Brien, MD, PhD, Roger J. Waltzman, MD, Manisha Mone, PhD, Elisabeth Wehrle, PhD, Jerald P. Radich, MD, John M. Goldman, MD

Blood (2008) 112 (11): 334.

https://doi.org/10.1182/blood.V112.11.334.334

Published: 2008

Journal Articles

International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM)

Stephen G O’Brien, MD, PhD, François Guilhot, MD, John M Goldman, DM, FRCP, Andreas Hochhaus, MD, Timothy P Hughes, MD, Jerald P. Radich, MD, Marc Rudoltz, MD, Jeiry Filian, Insa Gathmann, M.Sc., Brian J. Druker, MD, Richard A. Larson, MD

Blood (2008) 112 (11): 186.

https://doi.org/10.1182/blood.V112.11.186.186

Published: 2008

Journal Articles

IRIS 6-Year Follow-Up: Sustained Survival and Declining Annual Rate of Transformation in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Andreas Hochhaus, MD, Brian J. Druker, MD, Richard A. Larson, MD, Stephen G. O’Brien, MD, PhD, Insa Gathmann, Francois Guilhot, MD

Blood (2007) 110 (11): 25.

https://doi.org/10.1182/blood.V110.11.25.25

Published: 2007

Journal Articles

Imatinib Plasma Concentration and Sokal Risk Score Are Independently Prognostic for Complete Cytogenetic Response (CCyR) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).

Richard A. Larson, MD, Brian J. Druker, MD, Francois Guilhot, MD, Stephen G. O’Brien, MD, PhD, Tillman Krahnke, Insa Gathmann, Yanfeng Wang

Blood (2007) 110 (11): 1935.

https://doi.org/10.1182/blood.V110.11.1935.1935

Published: 2007

Journal Articles

Nilotinib Is Safe and Effective in Accelerated Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib Resistance or Intolerance.

Philipp le Coutre, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Jane Apperley, MD, Oliver G. Ottmann, MD, Norbert Gattermann, MD, PhD, Stephen G. O’Brien, MD, PhD, Kazimierz Kuliczkowski, Richard A. Larson, MD, Dong-Wook Kim, MD, PhD, Ariful Haque, Neil Gallagher, Michele Baccarani, MD, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 471.

https://doi.org/10.1182/blood.V110.11.471.471

Published: 2007

Journal Articles

Imatinib Dose Escalation Is Effective in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Hagop M. Kantarjian, MD, Brian J. Druker, MD, Francois Guilhot, MD, Jorge Cortes, MD, Stephen G. O’Brien, MD, PhD, Tillmann Krahnke, Richard A. Larson, MD

Blood (2007) 110 (11): 1047.

https://doi.org/10.1182/blood.V110.11.1047.1047

Published: 2007

Journal Articles

Time to Complete Cytogenetic Response (CCyR) Does Not Affect Long-Term Outcomes for Patients on Imatinib Therapy.

Francois Guilhot, MD, Richard A. Larson, MD, Stephen G. O’Brien, MD, PhD, Insa Gathmann, Brian J. Druker, MD

Blood (2007) 110 (11): 27.

https://doi.org/10.1182/blood.V110.11.27.27

Published: 2007

Journal Articles

A Gene Polymorphism within the Kinase Domain of BCR-ABL and Its Effects on Sensitivity to Tyrosine Kinase Inhibitors.

Lucy C. Crossman, MD, Thomas O’Hare, PhD, Thoralf Lange, MD, Stephanie G. Willis, Eric P. Stoffregen, Amie S. Corbin, Stephen G. O’Brien, MD, PhD, Michael C. Heinrich, MD, Brian J. Druker, MD, Peter G. Middleton, PhD, Michael W.N. Deininger, MD, PhD

Blood (2005) 106 (11): 1530.

https://doi.org/10.1182/blood.V106.11.1530.1530

Published: 2005

NARROW

Assessment Of Early Cytogenetic Response By 3 Months Versus >3-6 Months Or No Response By 6 Months As a Predictor Of Long-Term Clinical Outcomes In a Phase 1/2 Study Of Bosutinib In Chronic Phase CML

International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Steady-State Imatinib Trough Levels as Well as Dose Interruptions Are Associated with Clinical Response (CCyR and MMR) and Adverse Events (AEs) in Patients with Chronic Myeloid Leukemia (CML) Receiving IM as Frontline Therapy.

A Gene Expression Signature of CD34+ Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance.

Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP)

International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM)

IRIS 6-Year Follow-Up: Sustained Survival and Declining Annual Rate of Transformation in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Imatinib Plasma Concentration and Sokal Risk Score Are Independently Prognostic for Complete Cytogenetic Response (CCyR) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).

Nilotinib Is Safe and Effective in Accelerated Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib Resistance or Intolerance.

Imatinib Dose Escalation Is Effective in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Time to Complete Cytogenetic Response (CCyR) Does Not Affect Long-Term Outcomes for Patients on Imatinib Therapy.

A Gene Polymorphism within the Kinase Domain of BCR-ABL and Its Effects on Sensitivity to Tyrosine Kinase Inhibitors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only